DCA displays antagonist-like activity against FXR, whereas FXR agonists have demonstrated the potential to slow tumor progression, suggesting that FXR is likely involved in preserving colon health under high-fat dietary conditions [91]. The gene discussed is NR1H4; the disease is neoplasm.